JEANINE O'HAGAN: Open Payments
NPI 1679914360 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,655 in 14 payments from 9 companies in 2025. Trend: 2023 $241 · 2024 $879 · 2025 $1,655
Food & beverage: $1,655
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 4 | $458 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $223 |
| Amgen Inc. | 2 | $186 |
| Otsuka America Pharmaceutical, Inc. | 1 | $150 |
| Abbott Laboratories | 1 | $138 |
| Xeris Pharmaceuticals, Inc. | 1 | $135 |
| E.R. Squibb & Sons, L.L.C. | 1 | $126 |
| ABBVIE INC. | 1 | $124 |
| GlaxoSmithKline, LLC. | 1 | $114 |
Products named: Epclusa, KRYSTEXXA, REXULTI, FREESTYLE LIBRE 3, GVOKE HYPOPEN, COBENFY, Vemlidy, RINVOQ.
Industry payments across NY — which companies pay providers there.
